Goldman Sachs Reiterated a Buy Rating on Vertex Pharmaceuticals (VRTX), Kept the PT Unchanged

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the Most Profitable Large Cap Stocks to Buy According to Analysts. On August 11, Goldman Sachs analyst Salveen Richter reiterated a Buy rating on Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) with a price target of $624.

The reiterated bullish sentiment follows the announcement of strong fiscal second-quarter results by the company. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) delivered $2.96 billion during the quarter, reflecting a 12.06% increase year-over-year and ahead of expectations by $58.16 million. The EPS of $4.52 also exceeded expectations by $0.27. Management noted that this growth was driven by the successful launch of three products CASGEVY, ALYFTREK, and JOURNAVX. Moreover, its clinical programs for Suzetrigine, Zimislecel, Povetacicept, and Inaxaplin are also progressing quickly.

Looking ahead, management has reaffirmed its expected full-year revenue range of $11.85 billion to $12 billion.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company focused on developing transformative medicines for serious diseases, particularly in specialty markets.

While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.